Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes

The proprotein convertase subtilisin/kexin type 9 (PCSK9) acts via a canonical pathway to regulate circulating low-density lipoprotein-cholesterol (LDL-C) via degradation of the LDL receptor (LDLR) on the live...

Source: Cardiovascular Diabetology - March 13, 2020 Category: Cardiology Authors: Ying Tang, Sheng-Lan Li, Jia-Hui Hu, Kai-Jun Sun, Lei-Ling Liu and Dan-Yan Xu Tags: Review Source Type: research